Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 9, 2011

DuoCort Plenadren drug receives European approval

The European Commission has granted a European Marketing Authorisation for DuoCort Pharma's Plenadren, an orphan drug used to treat adrenal insufficiency in adults.

The European Commission has granted a European Marketing Authorisation for DuoCort Pharma’s Plenadren, an orphan drug used to treat adrenal insufficiency in adults.

Plenadren, an oral once-daily tablet, is a dual-release hydrocortisone replacement therapy.

The move follows the satisfactory opinion adopted by the Committee for Medicinal Products for Human Use.

DuoCort Pharma chief medical officer Gudmundur Johannsson said Plenadren could be a new cortisol replacement therapy for patients suffering from adrenal insufficiency.

Currently, Plenadren is approved in all European Union countries, Iceland, Norway and Lichtenstein.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU